[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550127":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":34,"collaborators":7,"id":36,"slug":7,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":41,"eligibilityCriteria":42,"healthyVolunteers":37,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":54,"overallStatus":61,"whyStopped":7,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Romain Brousse, MD, PhD","CONTACT","+33156017043","Romain.brousse@aphp.fr",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Boffa Jean-Jacques, MD, PhD","+33156016029","Jean-jacques.boffa@aphp.fr",[19],{"facility":20,"status":7,"city":21,"state":7,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Néphrologie & Dialyses department, Tenon Hospital","Paris","75020","France","FR",{"type":26,"coordinates":27},"Point",[28,29],2.3488,48.85341,{"lat":29,"lon":28},[32,33],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100550127",false,"NCT06443034","Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1","Predictive Determinants of Nephrotic Syndrome Remission in Patients With Focal Segmental Glomerulosclerosis or Minimal Change Disease and At-risk Polymorphism of APOL1 Gene","NEPHROL1","Inclusion Criteria:\n\n* Adult patients followed in 6 nephrology centers between 01\u002F01\u002F2016 and 01\u002F06\u002F2024.\n* With characterization of APOL1 gene risk status\n* Proteinuria\u002Fcreatinuria ratio \\> 3 g\u002Fg at diagnosis of renal disease (within 48 hours of the diagnostic renal biopsy)\n* Hypoalbuminemia \\\u003C 30 g\u002FL at diagnosis of renal disease (within 48 h of diagnostic renal biopsy)\n* Minimal change disease or segmental and focal hyalinosis lesions on renal biopsy.\n\nExclusion Criteria:\n\n* Presence of diffuse deposits of immunoglobulins or complement fractions on immunofluorescence study\n* Presence of endo- or extracapillary hypercellular lesions on light microscopy\n* Opposition to the use of medical data","ALL","18 Years",{"count":46,"type":47},124,"ESTIMATED","OBSERVATIONAL","This is a multicentric retrospective observational cohort study.\n\nAs primary objective, the study aims to evaluate the factors associated with nephrotic syndrome remission in patient with nephrotic syndrome, biopsy-prove minimal change disease or focal segmental glomerulosclerosis, and an at-risk variant of the APOL1 gene.\n\nAs secondary objectives, this study aims:\n\n* To evaluate the benefit of corticosteroids in obtaining the remission of nephrotic syndrome\n* To identify the predictors of complete renal remission of nephrotic syndrome\n* To evaluate the benefit of corticosteroids in reducing the incidence of end-stage renal disease\n* To assess the adverse events of corticosteroids in patients treated with corticosteroids.",[51,52,53],"Nephrotic Syndrome","Focal Segmental Glomerulosclerosis","APOL1 Associated Kidney Disease",[55,56,57,58,59,60],"Nephrotic syndrome","Covid-19 associated nephropathy","human immunodeficiency virus associated nephropathy","APOL1 associated kidney disease","Focal segmental glomerulosclerosis","Minimal change disease","NOT_YET_RECRUITING","2024-06-03",{"date":64,"type":65},"2024-06-05","ACTUAL",{"date":67,"type":47},"2024-06-30",{"date":69,"type":47},"2024-12-30",{"name":5,"class":6},1]